The development of high-dose GLP-1 RAs and dual GLP-1/GIP-RA tirzepatide resulted in increasing numbers of people reaching HbA1c and bodyweight targets, with up to 62% attaining normoglycaemia with 15 mg tirzepatide. Whether this will also translate in better cardiovascular outcomes and will affect treatment guidelines remains to be studied (Diabetes, Obesity and Metabolism)